{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:47Z","timestamp":1791478067664,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"\n Objective<\/jats:title>\n \n This 24\u2010week, phase\n II<\/jats:styled-content>\n b, double\u2010blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte\u2013macrophage colony\u2010stimulating factor receptor \u03b1) and golimumab (a monoclonal antibody to tumor necrosis factor [anti\u2010\n TNF<\/jats:styled-content>\n ]) in patients with rheumatoid arthritis (\n RA<\/jats:styled-content>\n ) who have had an inadequate response to disease\u2010modifying antirheumatic drugs (\n DMARD<\/jats:styled-content>\n s) (referred to as\n DMARD<\/jats:styled-content>\n \u2010\n IR<\/jats:styled-content>\n ) and\/or inadequate response to other anti\u2010\n TNF<\/jats:styled-content>\n agents (referred to as anti\u2010\n TNF<\/jats:styled-content>\n \u2013\n IR<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients with active\n RA<\/jats:styled-content>\n and a history of\u00a0\n DMARD<\/jats:styled-content>\n \u2010\n IR<\/jats:styled-content>\n (\u22651 failed regimen) or\n DMARD<\/jats:styled-content>\n \u2010\n IR<\/jats:styled-content>\n (\u22651 failed\u00a0regimen) and anti\u2010\n TNF<\/jats:styled-content>\n \u2013\n IR<\/jats:styled-content>\n (1\u20132 failed regimens) were randomized 1:1 to receive either mavrilimumab 100\u00a0mg subcutaneously every other week or golimumab 50 mg subcutaneously every 4 weeks alternating with placebo every 4 weeks, administered concomitantly with methotrexate. The primary end points were the American College of Rheumatology 20% improvement (\n ACR<\/jats:styled-content>\n 20), 50% improvement, and 70% improvement response rates at week 24, percentage of patients achieving a Disease Activity Score in 28 joints using C\u2010reactive protein level (\n DAS<\/jats:styled-content>\n 28\u2010\n CRP<\/jats:styled-content>\n ) of <2.6 at week 24, percentage of patients with a score improvement of >0.22 on the Health Assessment Questionnaire (\n HAQ<\/jats:styled-content>\n ) disability index (\n DI<\/jats:styled-content>\n ) at week 24, and safety\/tolerability measures. This study was not powered to formally compare the 2 treatments.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At week 24, differences in the\n ACR<\/jats:styled-content>\n 20,\n ACR<\/jats:styled-content>\n 50, and\n ACR<\/jats:styled-content>\n 70 response rates between the mavrilimumab treatment group (n = 70) and golimumab treatment group (n = 68) were as follows: in all patients, \u22123.5% (90% confidence interval [90%\n CI<\/jats:styled-content>\n ] \u221216.8, 9.8), \u22128.6% (90%\n CI<\/jats:styled-content>\n \u221222.0, 4.8), and \u22129.8% (90%\n CI<\/jats:styled-content>\n \u221221.1, 1.4), respectively; in the anti\u2010\n TNF<\/jats:styled-content>\n \u2013\n IR<\/jats:styled-content>\n group, 11.1% (90%\n CI<\/jats:styled-content>\n \u22127.8, 29.9), \u22128.7% (90%\n CI<\/jats:styled-content>\n \u221228.1, 10.7), and \u22120.7% (90%\n CI<\/jats:styled-content>\n \u221218.0, 16.7), respectively. Differences in the percentage of patients achieving a\n DAS<\/jats:styled-content>\n 28\u2010\n CRP<\/jats:styled-content>\n of <2.6 at week 24 between the mavrilimumab and golimumab groups were \u221211.6% (90%\n CI<\/jats:styled-content>\n \u221223.2, 0.0) in all patients, and \u22124.0% (90%\n CI<\/jats:styled-content>\n \u221220.9, 12.9) in the anti\u2010\n TNF<\/jats:styled-content>\n \u2013\n IR<\/jats:styled-content>\n group. The percentage of patients achieving a >0.22 improvement in the\n HAQ DI<\/jats:styled-content>\n score at week 24 was similar between the treatment groups. Treatment\u2010emergent adverse events were reported in 51.4% of mavrilimumab\u2010treated patients and 42.6% of golimumab\u2010treated patients. No deaths were reported, and no specific safety signals were identified.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The findings of this study demonstrate the clinical efficacy of both treatments, mavrilimumab at a dosage of 100 mg every other week and golimumab at a dosage of 50 mg every 4 weeks, in patients with\n RA<\/jats:styled-content>\n . Both regimens were well\u2010tolerated in patients who had shown an inadequate response to\n DMARD<\/jats:styled-content>\n s and\/or other anti\u2010\n TNF<\/jats:styled-content>\n agents.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/art.40323","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T10:36:51Z","timestamp":1505990211000},"page":"49-59","source":"Crossref","is-referenced-by-count":86,"title":["A Randomized Phase\n II<\/scp>\n b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis"],"prefix":"10.1002","volume":"70","author":[{"given":"Michael E.","family":"Weinblatt","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[{"name":"Glasgow Biomedical Research Centre Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[{"name":"Center for Rheumatology Albany New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Miranda","sequence":"additional","affiliation":[{"name":"Universidad de Chile and Hospital San Juan de Dios Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology Charles University Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"MedImmune Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy I.","family":"White","sequence":"additional","affiliation":[{"name":"MedImmune Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia C.","family":"Ryan","sequence":"additional","affiliation":[{"name":"MedImmune Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Godwood","sequence":"additional","affiliation":[{"name":"MedImmune Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Albulescu","sequence":"additional","affiliation":[{"name":"MedImmune Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Close","sequence":"additional","affiliation":[{"name":"MedImmune Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013University Medicine Berlin Free University of Berlin, and Humboldt University of Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390116"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S39770"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206578"},{"key":"e_1_2_8_6_1","first-page":"121","article-title":"Plasma GM\u2010CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy","volume":"51","author":"Fiehn C","year":"1992","journal-title":"Z Rheumatol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00262295"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205234"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02173.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202450"},{"issue":"10","key":"e_1_2_8_11_1","first-page":"S1231","article-title":"Efficacy and safety\/tolerability of mavrilimumab, a human GM\u2010CSFR\u03b1 monoclonal antibody in patients with rheumatoid arthritis [abstract]","volume":"66","author":"Burmester G","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210624"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2666"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20452"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes115"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v5.i4.504"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001311"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/528948"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286151104500409"},{"key":"e_1_2_8_28_1","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells GA","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068304"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0516-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"}],"container-title":["Arthritis & Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.40323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:34:14Z","timestamp":1759944854000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/art.40323"],"URL":"https:\/\/doi.org\/10.1002\/art.40323","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731259669.793564271","asserted-by":"object"}]},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}